Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Souheil G Abou-Assi

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Treatment Options in Gastroenterology|March 17, 2005
Gastric and Postpyloric Total Enteral NutritionSouheil G Abou-Assi, Vikash Khurana, Mitchell L Schubert
Inflammatory Bowel Diseases|October 13, 2009
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's diseaseAlan L Buchman, Seymour Katz, John C Fang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 15, 2005
High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhoticsAdil Habib, Anastasios A Mihas, Souheil G Abou-Assi, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|March 7, 2006
Safety of an immune-enhancing nutrition supplement in cirrhotic patients with history of encephalopathySouheil G Abou-Assi, Anastasios A Mihas, Edith A Gavis, et al.
Hepatology (Baltimore, Md.)|September 24, 2004
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early deathDouglas M Heuman, Souheil G Abou-Assi, Adil Habib, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Treatment Options in Gastroenterology|March 17, 2005
Gastric and Postpyloric Total Enteral NutritionSouheil G Abou-Assi, Vikash Khurana, Mitchell L Schubert
Inflammatory Bowel Diseases|October 13, 2009
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's diseaseAlan L Buchman, Seymour Katz, John C Fang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 15, 2005
High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhoticsAdil Habib, Anastasios A Mihas, Souheil G Abou-Assi, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|March 7, 2006
Safety of an immune-enhancing nutrition supplement in cirrhotic patients with history of encephalopathySouheil G Abou-Assi, Anastasios A Mihas, Edith A Gavis, et al.
Hepatology (Baltimore, Md.)|September 24, 2004
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early deathDouglas M Heuman, Souheil G Abou-Assi, Adil Habib, et al.
Pageof 1